ReutersReuters

The Board of Directors of F-Secure Corporation resolved on a directed share issue without consideration to the employees participating in the Employee Share Savings Plan

Refinitiv1 min read

F-Secure Corporation | Stock Exchange Release | 24 September 2025 at 10:30a.m. EEST

The Board of Directors of F-Secure Corporation resolved on a directed share issue without consideration to the employees participating in the Employee Share Savings Plan

The Board of Directors of F-Secure Corporation resolved, based on the authorization granted by the Annual General Meeting of Shareholders 1 April 2025, on a directed share issue without consideration to deliver the matching shares for the plan period 2022-2025 of the Employee Share Savings Plan (ESSP).

A total maximum of 33,905 new shares in the company will, in deviation from the shareholders’ pre-emptive right, be issued without consideration to the participants of the ESSP’s plan period 2022-2025. The company has a particularly weighty financial reason for the deviation from the shareholders’ pre-emptive right, as the shares are issued in accordance with the terms and conditions of the ESSP.

The new shares are estimated to be entered into the Trade Register and applied for public listing on Nasdaq Helsinki in October 2025. Following the entry of the new shares into the Trade Register, the total number of shares in the company will be 174,707,070.

Chief Financial Officer Sari Somerkallio, tel. +358 40 356 9251, investor.relations@f-secure.com For additional information, please contact:

F-Secure is Finland headquartered and globally operating consumer cyber security company. F-Secure offers award-winning security and privacy products and services that make every digital moment more secure, for everyone. F-Secure operates in over 100 countries, has ~200 Service Provider partners and is the global leader providing security through Communication Service Providers. F-Secure Corporation is listed on Nasdaq Helsinki Ltd. F-Secure in brief

Read more: www.f-secure.com 

Login or create a forever free account to read this news